Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides

Background: A series of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides was synthesized and characterized by physicochemical and spectral means. The synthesized compounds were evaluated for their in vitro antimicrobial activity against Staphylococcus aureus, Bacillu...

Full description

Bibliographic Details
Published in:Chemistry Central Journal
Main Author: Yadav S.; Narasimhan B.; Lim S.M.; Ramasamy K.; Vasudevan M.; Shah S.A.A.; Selvaraj M.
Format: Article
Language:English
Published: BioMed Central Ltd. 2017
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038963723&doi=10.1186%2fs13065-017-0361-6&partnerID=40&md5=46d6699cfc1e43d521c40070abbc69f4
id 2-s2.0-85038963723
spelling 2-s2.0-85038963723
Yadav S.; Narasimhan B.; Lim S.M.; Ramasamy K.; Vasudevan M.; Shah S.A.A.; Selvaraj M.
Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides
2017
Chemistry Central Journal
11
1
10.1186/s13065-017-0361-6
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038963723&doi=10.1186%2fs13065-017-0361-6&partnerID=40&md5=46d6699cfc1e43d521c40070abbc69f4
Background: A series of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides was synthesized and characterized by physicochemical and spectral means. The synthesized compounds were evaluated for their in vitro antimicrobial activity against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Candida albicans and Aspergillus niger by tube dilution method. The in vitro cytotoxicity study of the compounds was carried out against human colorectal (HCT116) cell line. The most promising anticancer derivatives (5l, 5k, 5i and 5p) were further docked to study their binding efficacy to the active site of the cyclin-dependent kinase-8. Results: All the compounds possessed significant antimicrobial activity with MIC in the range of 0.007 and 0.061 μM/ml. The cytotoxicity study revealed that almost all the derivatives were potent in inhibiting the growth of HCT116 cell line in comparison to the standard drug 5-fluorouracil. Compounds 5l and 5k (IC50 = 0.00005 and 0.00012 μM/ml, respectively) were highly cytotoxic towards HCT116 cell line in comparison to 5-fluorouracil (IC50 = 0.00615 μM/ml) taken as standard drug. Conclusion: The molecular docking studies of potent anticancer compounds 5l, 5k, 5i and 5p showed their putative binding mode and significant interactions with cyclin-dependent kinase-8 as prospective agents for treating colon cancer. © 2017 The Author(s).
BioMed Central Ltd.
1752153X
English
Article
All Open Access; Gold Open Access; Green Open Access
author Yadav S.; Narasimhan B.; Lim S.M.; Ramasamy K.; Vasudevan M.; Shah S.A.A.; Selvaraj M.
spellingShingle Yadav S.; Narasimhan B.; Lim S.M.; Ramasamy K.; Vasudevan M.; Shah S.A.A.; Selvaraj M.
Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides
author_facet Yadav S.; Narasimhan B.; Lim S.M.; Ramasamy K.; Vasudevan M.; Shah S.A.A.; Selvaraj M.
author_sort Yadav S.; Narasimhan B.; Lim S.M.; Ramasamy K.; Vasudevan M.; Shah S.A.A.; Selvaraj M.
title Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides
title_short Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides
title_full Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides
title_fullStr Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides
title_full_unstemmed Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides
title_sort Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides
publishDate 2017
container_title Chemistry Central Journal
container_volume 11
container_issue 1
doi_str_mv 10.1186/s13065-017-0361-6
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038963723&doi=10.1186%2fs13065-017-0361-6&partnerID=40&md5=46d6699cfc1e43d521c40070abbc69f4
description Background: A series of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides was synthesized and characterized by physicochemical and spectral means. The synthesized compounds were evaluated for their in vitro antimicrobial activity against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Candida albicans and Aspergillus niger by tube dilution method. The in vitro cytotoxicity study of the compounds was carried out against human colorectal (HCT116) cell line. The most promising anticancer derivatives (5l, 5k, 5i and 5p) were further docked to study their binding efficacy to the active site of the cyclin-dependent kinase-8. Results: All the compounds possessed significant antimicrobial activity with MIC in the range of 0.007 and 0.061 μM/ml. The cytotoxicity study revealed that almost all the derivatives were potent in inhibiting the growth of HCT116 cell line in comparison to the standard drug 5-fluorouracil. Compounds 5l and 5k (IC50 = 0.00005 and 0.00012 μM/ml, respectively) were highly cytotoxic towards HCT116 cell line in comparison to 5-fluorouracil (IC50 = 0.00615 μM/ml) taken as standard drug. Conclusion: The molecular docking studies of potent anticancer compounds 5l, 5k, 5i and 5p showed their putative binding mode and significant interactions with cyclin-dependent kinase-8 as prospective agents for treating colon cancer. © 2017 The Author(s).
publisher BioMed Central Ltd.
issn 1752153X
language English
format Article
accesstype All Open Access; Gold Open Access; Green Open Access
record_format scopus
collection Scopus
_version_ 1792585534165483520